subjective tinnitus for 4 weeks to 1 year tinnitus Ginkgo biloba tinnitus handicap inventory HADS
Conditions
Interventions
The intervention group is received Ginkgo biloba extract EGb761 with dose of 120 mg/tablet twice daily (240 mg/day/participant) by oral route for 3 months.
,The control group is received Ginkgo bilob
Placebo Comparator Drug,Placebo Comparator Drug
Ginkgo biloba extract EGb761,Control
Sponsors
Ratchadaphiseksomphot Endowment Fund
Eligibility
Sex/Gender
All
Age
18 Years to No maximum
Inclusion criteria
Inclusion criteria: 1. Age over 18 years old 2. Unilateral or bilateral subjective tinnitus 3. Tinnitus for 4 weeks to 1 years 4. Any medication taken to treatment tinnitus has to be discontinues at least 1 month
Exclusion criteria
Exclusion criteria: 1. Current otitis media 2. Taking other treatment for tinnitus included hearing aid, sound therapy, cognitive-behavioral therapy for tinnitus. 3. Severe cardiovascular, renal or hepatic disorder 4. Psychological problem such as schizophrenia, schizophreniform disorder, schizoaffective disorder, brief psychotic disorder, delusional disorder, anxiety, depression 5. Neurodegenerative disease such as delirium, dementia, Parkinson, Alzheimer 6. Pregnancy or childbearing 7. Illegible 8. Allergic to the investigational drug
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Tinnitus Handicap Inventory Score 3 months Tinnitus Handicap Inventory Score | — |
Secondary
| Measure | Time frame |
|---|---|
| Hospital Anxiety and Depression Scale 3 months Hospital Anxiety and Depression Scale,tinnitus loudness 3 months visual analog scale | — |
Countries
Thailand
Contacts
Public ContactPaninee Charusripan
Chulalongkorn University
Outcome results
None listed